AKD assists Ncardia with US$60+ million investment by Kiniciti

November 18, 2021 | News

AKD has assisted Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, and its shareholders in securing more than US$60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide. Kiniciti is backed by Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm investing in healthcare and technology, and Biospring Partners. The transaction gives Kiniciti a controlling stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to commercial production.

About Ncardia
Ncardia is a human iPSC technology company developing stem cell-based solutions for drug discovery and cell therapy that operates worldwide with facilities, offices, and staff throughout Europe and North America.

About Kiniciti
Kiniciti, a platform company of leading private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners, invests in and partners with companies that have the potential to transform and strengthen the cell and gene therapy ecosystem.

About Welsh, Carson, Anderson & Stowe
WCAS is a leading private equity firm focused on two target industries: technology and healthcare. The firm has raised and managed funds totaling over $27 billion of committed capital.


AKD's team consisted of Timothy Speelman and Nathalie Locht. Read more here.

Sign up for our newsletters